


Posttranslational Modification of Histone Deacetylase 2 in Cardiac Hypertrophy

Hyun Kook, MD, PhD

*Department of Pharmacology and
Medical Research Center for Gene Regulation
Chonnam National University Medical School,
Gwangju, South Korea*



Cardiac Hypertrophy




Hill JA and Olson EN., *N Engl J Med.* **358**:1370–1380 (2008).

hyper-acetylation = transcription activation

Histone acetylation




<http://www.rikenresearch.riken.jp/eng/frontline/5568>



HAT (histone acetyltransferase)
p300, pCAF, Tip60
Gcn, Esa, etc

Class II HDAC in cardiac hypertrophy



Bush & McKinsey
Expert Opin Ther Targets
2009

Paradoxical Effects of HDAC inhibitors:

Kook et al., *J Clin Invest* 2003

Class I HDAC inhibitor blocks TAC-induced cardiac hypertrophy

Kee et al., *Circulation*, 2006

Activation of HDAC2 by HSP70

Kee & Eom et al., *Circ Res* 2008

KLF4 is a downstream of HDAC2


Kee & Kook, *J Mol Cell Cardiol* 2009

CK2 α 1-induced Hdac2 S394 phosphorylation & activation












Eom et al., *Circulation*, 2011

Class II: anti-hypertrophic vs Class I: pro-hypertrophic

Kee & Kook, *J Biomed Biotechnol* 2011



PTM of HDACs and their implications in CV diseases

Class	Structure	HDAC inhibitors
I	HDAC1 	SK-7041 Apicidin, MS-275 Desipeptide Trichostatin A, Vorinostat (SAHA), Scriptaid Butyrate, Valproic acid
	HDAC2 	
	HDAC3 	
	HDAC8 	
IIa	HDAC4 	MC-1568 Tubacin
	HDAC5 	
	HDAC7 	
	HDAC9 	
IIb	HDAC6 	Tubacin
	HDAC10 	
IV	HDAC11 	

Part 1

Regulation of acetylation of
HDAC2 by pCAF/HDAC5 in
cardiac hypertrophy

**HDAC2 K75 acetylation activates
HDAC2 in cardiac hypertrophy**


Hypertrophic stresses acetylate HDAC2

HDAC2 acetylation results in HDAC2 activation


Garcinol: HAT inhibitor, acetylation ↓

TSA: class I & class II HDAC inhibitor, acetylation ↑

Apicidin: class I HDAC inhibitor, acetylation ↑




IP-based acetylation assay




Hdac2 activity

HDAC2 K75 is an acetylation target and is required for HDAC2 activation




Hdac2 K75R: by site-directed mutagenesis
 acetylation-resistant mutant

IP-based acetylation assay




HDAC activity assay


HDAC2 K75R blunts agonist-induced hypertrophy



Leucine incorporation (protein synthesis) assay




Direct cardiomyocyte size measurement after fluorescent ICC




**HDAC2 K75 acetylation induces
HDAC2 S394 phosphorylation**

Hypothesis: acetylation vs phosphorylation


1. P-dependent Ac



2. Ac-dependent P




3. Independent




HDAC2 phosphorylation is reduced in K75R


HDAC2 acetylation is NOT affected by S394A



HDAC2 acetylation
induces S394
phosphorylation




IP-based acetylation assay



Phosphorylation assay with pS394-specific Ab


Phospho-dead
HDAC2 still could
be acetylated



IP-based acetylation assay

but,,, HDAC2
phosphorylation is
required in
acetylation-mediated
HDAC2 activation

E



HDAC2 activity




Hdac2 K75R: acetylation-resistant

Hdac2 S394A: hypertrophy-associated phosphorylation-resistant

Hdac2 S394/422/424A: all phospho-resistant

Hdac2 H141A: enzyme-activity-dead, by disruption of pocket structure

HDAC2 S394 phosphorylation is required in acetylation-mediated HDAC2 activation & cardiac hypertrophy



Hdac2 K75R: acetylation-resistant

Hdac2 K75Q: acetylation-mimic

Hdac2 S394A: phospho-resistant

Hdac2 K75Q/S394A: acetylation-mimic, but phospho-resistant

**pCAF / HDAC5 regulates
HDAC2 acetylation**





Which HAT ??? pCAF !!!

P300 does not interact with, nor acetylates HDAC2


pCAF interacts with HDAC2

acetylates HDAC2_{,,,}

and induces cardiac hypertrophy



F




Which HDAC ??? HDAC5 !!!

HDAC2 interacts with HDAC5,,, and with HDAC9

but, HDAC9 failes to deacetylate HDAC2

only HDAC5 deacetylates HDAC2 !!!




HDAC5 interplays with HDAC2 to regulate cardiac hypertrophy

LMB: enhances class II HDAC action by tethering class II HDAC in the nucleus



HDAC2 K75Q: acetylation-mimicking mutant

HDAC2-induced hypertrophy is blocked by enhancing HDAC5 action

B



A



HDAC2
cardiac
HDAC5

Increase in H
acetylation &
phosphoryla
HDAC5 knock

Tail vein injec
adeno-HDAC
HDAC5 knock




Figure 7. Working hypothesis. In the basal condition, HDAC5 inhibits HDAC2 by deacetylation (**left**). When hypertrophic stresses stimulate the myocardium, phosphor-HDAC5 is exported to the cytoplasm. Casein kinase 2 α 1 (CK2 α 1) is shuttled into the nucleus and phosphorylates HDAC2, and p300/CBP-associated factor (pCAF) binds to HDAC2 and induces acetylation. Activated HDAC2 induces hypertrophy of the myocardium to satisfy the increased hemodynamic requirement (**right**). Ac indicates acetylation; and P, phosphorylation.

Ad-HDAC2 K75R	-	-	+	-	-	+
ISP	-	+	+	-	+	+
	Wild type			Hdac5 KO		
	-	-	+	-	-	+
	-	+	+	-	+	+


Eom et al., *Circ Res* 114:1133-1143, 2014a

Part 2

PP2A/HSP70 dynamically
regulates HDAC2
phosphorylation

Hypothesis



Phosphorylation regulation mechanism other than CK2 α 1?



**Protein phosphatase 2A
attenuates hypertrophy by
dephosphorylation of HDAC2**

PP2A binds to and Ca^{2+} -phosphorylates HDAC2

PP2A inhibits HDAC2 activity




Yeast one-to-one


pGBKT7-HDAC2 / pGADT7-PP2R5A

B


PP2CA-Myc + +
HDAC2-V5 - +




C



D



E




PP2CA inhibits cardiac hypertrophy

by dephosphorylating HDAC4 (Ling et al., 2012)

by dephosphorylating HDAC2 ?


CKIP-1 Inhibits Cardiac Hypertrophy by Regulating Class II Histone Deacetylase Phosphorylation Through Recruiting PP2A

Shukuan Ling, PhD*; Qiao Sun, MD, PhD*; Yuheng Li, MA; Luo Zhang, MD; Pengfei Zhang, MA; Xiaogang Wang, MD; Chunyan Tian, MD, PhD; Qi Li, MA; Jinping Song, MD; Hongju Liu, BA; Guanghan Kan, MA; Hongqing Cao, MA; Zengming Huang, BA; Jieli Nie, BA; Yanqiang Bai, MD; Shanguang Chen, PhD; Yinghui Li, PhD; Fuchu He, PhD; Lingqiang Zhang, PhD; Yingxian Li, PhD




Ling et al. Circulation. 2012; 126:3 028-3040


A




B



PP2CA dissociates from HDAC2 by hyperphosphorylation stress or by HDAC2 acetylation




A




IP: HDAC2
WT or KR
IB: PP2CA

B



C




**HSP70 specifically binds to
phosphorylated HDAC2 to
maintain its activity**

Phospho-HDAC2-specific binding partners

Protein-precipitation with biotinylated peptide

Bait: (biotin-conjugated) 15 amino acid-long peptide of HDAC2 flanking S394A (S->A, negative)
or S394E (S->E, mimic)




Prey: mouse heart lysates



Kee & Eom et al., *Circ Res.* **103**: 1259-1269, 2008.




HSP70 preferentially binds to phosphorylated HDAC2

HSP70 is required for phosphorylation of HDAC2






HSP70 interferes with binding of PP2CA to HDAC2

HSP70 protects HDAC2 activity from PP2CA



HDAC2 K75 acetylation is required for binding of HSP70 to HDAC2



Hypothesis

Hypertrophic Stimuli



CK2 α 1

Cytoplasm



pCAF

PP2A
Hdac2

HDAC5

Nucleus


Ac Ac Ac Ac

KLF4? Inpp5f? promoter Turn Off

KLF4?
Inpp5f?

Fetal gene HDRE Turn Off

Cardiac hypertrophy



Acknowledgement

KOOK Lab

Gwang Hyeon Eom, MD, PhD, Assistant Professor

Hosouk Joung, PhD

Duk-wha Kwon, PhD

Yoonseok Nam, PhD Candidate

Nakwon Choe, MS

Sera Shin, BS

Hyun-Ki Min, BS

Taewon Kook, BS

Eun Mi Kim, Lab. Manager

Young Guk Cho, animal model, echocardiogram, MD, PhD, Department of Pediatrics

Collaborators

Kwang-II Nam, histology, MD, PhD, Department of Anatomy

Jung-Joon Min, tail vein injection, MD, PhD, Department of Nuclear Medicine

Woo-Jin Park, adult cardiomyocytes, PhD, Department of Life Science, GIST

In-Kyu Lee, adenovirus, MD, PhD, Kyungbook University

Eric Olson, HDAC5 ko animal, PhD, UT Southwestern

Rhonda Bassel-Duby, HDAC5 ko animal & data discussion, PhD, UT Southwestern

Jonathan A. Epstein, data discussion & mentor, MD, University of Pennsylvania

